

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Customer No. 21378

Docket No.: 3395-US

Examiner: Not yet assigned

In re application of:
Lee L. Swanstrom
)
Serial No. 10/053,053
)
Filed: January 16, 2002
)
For: LAPAROSCOPIC-ASSISTED ENDOVASCULAR/)
ENDOLUMINAL GRAFT PLACEMENT
)

Date of Deposit: January <u>27</u>, 2006

I hereby certify that the following documents as identified below are being deposited with Federal Express Service on the date indicated above in an envelope addressed to United States Patent and Trademark Office, Customer Service Window, Mail Stop Amendments, Randolph Building, 401 Dulany Street, Alexandria, VA 22314.

- 1. Information Disclosure Statement;
- 2. PTO Form PTO/SB/08a;
- 3. Copies of cited references (10);
- 4. PTO Form PTO/SB/08B;
- 5. Copies of cited references (101)
- 6. Transmittal;
- 8. Return-receipt postcard.

Each of the above-identified documents is enclosed herewith.

Respectfully submitted,

Rosanne Henehan

**Applied Medical Resources Corporation** 

seanne Henchan

**CUSTOMER NO.: 21378**Telephone (949) 713-8000
Facsimile (949) 713-8206

JAN 8 0 2006 By

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no	persons	are required to respond to a collection	n of inform	ation unles	s it disola	vs a valid OMB control number.
		Application Number	10/053,05	53		
TRANSMITTAL		Filing Date	January 1	6, 2002		
FORM	First Named Inventor	Lee L. Sw	Lee L. Swanstrom			
(to be used for all correspondence after initial filing	Art Unit	3731				
		Examiner Name	Not yet as	ssigned.		
Total Number of Bassa in This Submission 118	88	Attorney Docket Number	3395-US	.,		
Total Number of Pages in This Submission			!			
	ENCL	OSURES (Check all that	apply)			<u> </u>
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application		Orawing(s)  Licensing-related Papers  Petition  Petition to Convert to a  Provisional Application  Power of Attorney, Revocation  Change of Correspondence Addre  Ferminal Disclaimer  Request for Refund  CD, Number of CD(s)	Eess [	Ap of . Ap (As PTO Form (10); PTO	peal Cor Appeals peal Cor opeal Not oprietary atus Lette her Enckentify bell SB08a as Form SB0	osure(s) (please
Response to Missing Parts under 37 CFR 1.52 or 1.53						
	RE O	F APPLICANT, ATTORNI	EY, OR	AGEN'	Τ	
Firm or Individual name  Signature  Date  CYNTHIA BONNER  CYNTHIA BONNER  1 - 27 - 06	nes			-		
CER	TIFIC	ATE OF TRANSMISSION	/MAILI	NG		
CERTIFICATE OF TRANSMISSION/MAILING  I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.						
Typed or printed name Rosanne Henehan						
Signature		Dundar			Date	427-06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re application of:	) Customer No. 2	1378
----------------------	------------------	------

Lee L. Swanstrom

Serial No. 10/053,053 ) Attorney's Docket: 3395-US

Filed: January 16, 2002 )

For: LAPAROSCOPIC-ASSISTED ENDOVASCULAR/)

ENDOLUMINAL GRAFT PLACEMENT

Mail Stop Amendment Commissioner for Patents Alexandria, VA 22313-1450 Facsimile No.: (703) 872-9306

#### INFORMATION DISCLOSURE STATEMENT

#### Dear Sir/Madam:

Enclosed please find a copy of PTO/SB/08a which lists information which may be relevant to the prosecution of the above-captioned application. It is requested that this information be considered by the Office.

This Statement is being submitted under the terms of 37 C.F.R. § 1.97(b). The information is being filed before the mailing of a first Office Action on the merits. Therefore, it is believed no fee is due.

Under 37 C.F.R. § 1.97(h), it is understood that filing of the Information Disclosure Statement does not constitute an admission that the information submitted is material to patentability.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any over-payment, to our Deposit Account No.01-2215.

Respectfully submitted,

Cynthia Bonner

Attorney for Applicant Registration No. 44,548

Date: January <u>27</u> 2006

Customer No. 21378

Telephone (949) 713-8000 Facsimile (949) 713-8206

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ct of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/053,053		
Filing Date	January 16, 2002		
First Named Inventor	Lee L. Swanstrom		
Art Unit	3731		
Examiner Name	Not yet assigned.		
Attorney Docket Number	3395-US		

Sheet	1	of 3	-	Attorney Docket Number	3395-US	
			II S PATEN	DOCUMENTS		
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Docu		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		<sup>US-</sup> 5,707,378	01-13-1998	Ahn et al.		· · · · · · · · · · · · · · · · · · ·
	ļ	<sup>US-</sup> 5,527,355	06-18-1996	Ahn		
		<sup>US-</sup> 5,843,170	12-01-1998	Ahn		
		<sup>US-</sup> 5,538,735	07-23-1996	Ahn		
		<sup>US-</sup> 6,669,707 B1	12-30-2003	Swanstrom et al.		
		<sup>US-</sup> 357,813	02-15-1887	W. P. Brown		
		<sup>US-</sup> 1,525,408	02-03-1925	L.G. Miller et al.		
	ļ	<sup>US-</sup> 5,067,957	11-26-1991	Jervis		
		<sup>US-</sup> 6,514,265 B2	02-04-2003	Ho et al.		
	,	<sup>US-</sup> 6,709,442 B2	03-23-2004	Miller et al.		
		<sup>US-</sup> 2001/0008970 A1	07-19-2001	Ravenscroft et al.		· • •
		<sup>US-</sup> 4,705,040	11-10-1987	Mueller et al.		
		<sup>US-</sup> 4,790,090	12-13-1988	Sharber		
		US- 5,273,052	12-28-1993	Kraus et al.		
		Uṣ- 5,700,277	12-23-1997	Nash et al.		
		<sup>US-</sup> 5,383,896	01-24-1995	Gershony et al.		
		<sup>US-</sup> 5,741,325	04-21-1998	Chaikof et al.		
		<sup>US-</sup> 2001/0044651 A1	11-22-2001	Steinke et al.		
		<sup>US-</sup> 2001/0000903 A1	05-10-2001	Heck et al.		

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Cite Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	Т
		FR 2 773 058	11-24-1998	B. Braun Celsa		
		WO 97/39687 A1	10-30-1997	Ahn, Sam S.		
		WO 99/33402 A1	07-08-1999	Swanstrom, Lee L.		
		EP 0983024 A1	12-04-2002	Swanstrom, Lee L.		
		WO 90/15582 A1	12-27-1990	Trout, Hugh H., III		
		EP 0 236 427 B1	08-04-1993	Acufex Microsurgical Inc.		Г

Examiner	 I Data	
	Date	
Signature	Considered	
- · <b>3</b> · · · · · · ·	00	ł

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

Sheet 2

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/053,053		
Filing Date	January 16, 2002		
First Named Inventor	Lee L. Swanstrom		
Art Unit	3731		
Examiner Name	Not yet assigned.		
Attorney Docket Number	3395-US		

	1	, <u>.</u>		DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	<del>                                     </del>	<sup>US-</sup> 6,149,658	11-21-2000	Gardiner et al.	
		<sup>US-</sup> 6,190,397	02-20-2001	Spence et al.	
	-	<sup>US-</sup> 6,432,123 B2	08-13-2002	Schwartz et al.	
		<sup>US-</sup> 6,730,112 B2	05-04-2004	Levinson	
		<sup>US-</sup> 6,248,116 B1	06-19-2001	Chevillon et al.	
		<sup>US-</sup> 5,824,055	10-20-1998	Spiridigliozzi et al.	
		<sup>US-</sup> 6,187,015 B1	02-13-2001	Brenneman	
		<sup>US-</sup> 6,167,605 B1	01-02-2001	Morales	
		<sup>US-</sup> 6,217,585 B1	04-17-2001	Houser et al.	
		<sup>US-</sup> 5,649,959	07-22-1997	Hannam et al.	
		<sup>US-</sup> 5,810,884	09-22-1998	Kim	
		<sup>US-</sup> 6,214,038 B1	04-10-2001	Piplani et al.	
		<sup>US-</sup> 5,843,084	12-01-1998	Hart et al.	
		<sup>US-</sup> 6,626,919 B1	09-30-2003	Swanstrom	
		US- 2001/0053924 A1	12-20-2001	Trout, III et al.	
		US- 2001/0056273 A1	12-27-2001	Ewers, Richard C.	
		<sup>US-</sup> 5,814,072	09-29-1998	Bonutti	
		<sup>US-</sup> 6,077,250	06-20-2000	Snow et al.	
		<sup>US-</sup> 6,315,789 B1	11-13-2001	Cragg	

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	┖
		WO 97/41804 A1	11-13-1997	B. Braun Celsa		
		WO 99/16384 A1	04-08-1999	B. Braun Celsa		
		WO 99/30637 A1	06-24-1999	B. Braun Celsa		
		FR 2 773 057	12-29-1997	B. Braun Celsa	-	
						Γ

Examiner		Date	
Signature		Considered	
		00.10.00.00	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Sheet 3

(Use as many sheets as necessary)

Complete if Known		
Application Number	10/053,053	
Filing Date	January 16, 2002	
First Named Inventor	Lee L. Swanstrom	
Art Unit	3731	
Examiner Name	Not yet assigned.	
Attorney Docket Number	3395-US	

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code <sup>2 (# known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear
		<sup>US-</sup> 6,312,448 B1	11-06-2001	Bonutti	
		<sup>US-</sup> 6,306,159 B1	10-23-2001	Schwartz et al.	•
		<sup>US-</sup> 6,110,183	08-29-2000	Соре	
		<sup>US-</sup> 6,059,800	05-09-2000	Hart et al.	
		<sup>US-</sup> 6,033,430	03-07-2000	Bonutti	
		<sup>US-</sup> 5,954,732	09-21-1999	Hart et al.	
		<sup>US-</sup> 5,948,002	09-07-1999	Bonutti	
		<sup>US-</sup> 5,814,071	09-29-1998	McDevitt et al.	
		<sup>US-</sup> 5,626,614	05-06-1997	Hart	
		US-			
		US-	***		
		US-			
		US-			
		US-		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
		US-			

 	FORE	IGN PATENT DOCU	MENTS		
Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Country Code <sup>3 -</sup> Number <sup>4 -</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵

Examiner		 	Date	
Signature			Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/053,053 INFORMATION DISCLOSURE Filing Date January 16, 2002 STATEMENT BY APPLICANT First Named Inventor Lee L. Swanstrom Art Unit 3731 (Use as many sheets as necessary) **Examiner Name** Not yet assigned. Attorney Docket Number Sheet 11 3395-US of

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DAVID C. BREWSTER, MD, Presidential address: What would you do if it were your father? Reflections on endovascular abdominal aortic aneurysm repair, Journal of Vascular Surgery, June 2001, Volume 33, Number 6., Clinical Research Studies from New England Society for Vascular Surgery, Boston Mass.	
		B.A. JOBE, W. DUNCAN, L.L. SWANSTROM, Totally laparoscopic abdominal aortic aneurysm repair, Surgical Endoscopy Ultrasound and Interventional Techniques, 1999, 13: 77-79, Springer-Verlag, New York.	
		RALF KOLVENBACH, MD, PHD; LOUIS DA SILVA, MD; OLAF DELING, MD; ELISABETH SCHWIERZ, MD; Video-Assisted Aortic Surgery, J Am Coll Surg, April 2000, Vol. 190, No. 4, pp. 451-457, Elsevier Science Inc	
		SONESSON B, MONTGOMERY A, IVANCEV K, LINDBLAD B, Fixation of infrarenal aortic stent-grafts using laparoscopic banding - an experimental sample study in pigs, Eur J Vasc Endovasc Surg, 2001 Jan; 21 (1): 40-5.	
		MARK WHITE, Surgeons at Henrico Doctors' Hospital Perform World's First Fully Laparoscopic Robotically Assisted Aortic Graft, Henrico Doctors' Hospital News Release, June 5, 2001, Richmond, Virginia.	
		M. MEHTA, T. OHKI, F. J. VEITH, E. C. LIPSITZ, All Sealed Endoleaks are not the Same: A Treatment Strategy Based on an ex-vivo Analysis, European Journal of Vascular and Endovascular Surgery, June 2001, Volume 21, Number 6, pp. 541-544.	
		T. RESCH, M. MALINA, B. LINDBLAD, K. IVANCEV, The Impact of Stent-graft Development on Outcome of AAA Repair - a 7-Year Experience, European Journal of Vascular and Endovascular Surgery, July 2001, Volume 22, Number 1, pp. 57-61.	
		NUNO V. DIAS, TIMOTHY RESCH, MD, PHD; MARTIN MALINA, MD PHD; BENGT LINDBLAD, MD, PHD; and KRASSI IVANCEV, MD, PHD; Intraoperative Proximal Endoleaks During AAA Stent-Graft Repair: Evaluation of Risk Factors and Treatment with Palmaz Stents, J Endovasc Ther, 2001, 8:268-273.	
		CARSTEN HEINTZ; GUNNAR RIEPE, MD; LARS BIRKEN; EDELGARD KAISER, PHD; NABIL CHAKFE, MD, PHD; MICHAEL MORLOCK, PHD; GUNTER DELLING, MD; and HERBERT IMIG, MD; Corroded Nitinol Wires in Expanded Aortic Endografts: An Important Mechanism of Failure?, J Endovasc Ther, 2001, 8:248-253.	
		ZARINS ET AL., Will Endovascular Repair Replace Open Surgery for Abdominal Aortic Aneurysm Repair?, Annals of Surgery, October 2000, Vol 232, No. 4, pp. 501-507, Lippincott Williams & Wilkins, Inc	

Examiner	 Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Onsidered. Include Copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known ute for form 1449/PTO **Application Number** 10/053,053 INFORMATION DISCLOSURE **Filing Date** January 16, 2002 STATEMENT BY APPLICANT **First Named Inventor** Lee L. Swanstrom Art Unit 3731 (Use as many sheets as necessary) **Examiner Name** Not yet assigned. Attorney Docket Number Sheet 3395-US 11 Ωf

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		CHUTER ET AL., Endoleak after endovascular repair of abdominal aortic aneurysm, Journal of Vascular Surgery, July 2001, Volume 34, Number 1, pp.98-105.	
		NAJIBI ET AL, Detection of isolated hook fractures 36 months after implantation of the Ancure endograft: A cautionary note, Journal of Vascular Surgery, August 2001, Volume 34, Number 2, pp.353-356.	
		JACK L. CRONENWATT, MD, What's new in vascular surgery, JACS, February 2001, Correspondence address accepted Nov. 1, 2000, Dartmouth-Hitchcock Medical Center, Lebanon, NH.	
		M M THOMPSON, Arterial aneurysms (ABC of Arterial and Venous Disease), British Medical Journal, April 29, 2000.	
		JOANNE K PHILLIPS, Abdominal aortic aneurysms: confronting a compound problem, British Medical Journal, May 1998.	
		GL GILLING-SMITH ET AL., The Significance of Endoleaks After Endovascular AAA Repair: Results of A Large European Multicenter Study, J Endovasc Surg, 1998, 5:I-1-I-40.	
		BLUM ET AL., Endoluminal Stent-Grafts for Infrarenal Abdominal Aortic Aneurysms, The New England Journal of Medicine, January 2, 1997, Volume 336, Number 1, pp.13-20.	
		SICARD ET AL., Endoluminal Graft Repair for Abdominal Aortic Aneurysms in High-Risk Patients and Octogenarians, Annals of Surgery, October 2001, Vol. 234, No. 4, pp. 427-437, Lippincott Williams & Wilkins, Inc	
		GUIDANT CORPORATION, New Guidant-Sponsored CME Program on Medscape.com to Raise Awareness of Silent Killer, BusinesWire/HealthWire, Oct. 10, 2000, Indianapolis, IN.	
		MARTIN MALINA, MD, PHD, Mechanisms of Aortic Stent-Graft Migration And Disruption: Can They Be Prevented?, Combined Session: Vascular Surgery and Interventional Radiology, IV 6.1-6.4.	

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/053,053 INFORMATION DISCLOSURE **Filing Date** January 16, 2002 STATEMENT BY APPLICANT **First Named Inventor** Lee L. Swanstrom Art Unit 3731 (Use as many sheets as necessary) **Examiner Name** Not yet assigned. Attorney Docket Number Sheet 3395-US 3 of 11

		NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HUGH H. TROUT III, MD, and HOWARD M. TANNER, A new vascular Endostaple: A technical description, Journal of Vascular Surgery, September 2001, Volume 34, Number 3, pp. 565-568.	
		DION ET AL., Will Laparascopic Aortic Surgery Replace Most Open And Endovascular Procedures?, 28th Global: Vascular and Endovascular Issues, Techniques and Horizons TM, XV 4.1 - 4.5.	
		EDWARD B. DIETHRICH, MD, What is the Future of Aortic Surgery? What Will Be The Roles Of Endovascular, Open And Laparoscopic Procedures?, 28th Global: Vascular and Endovascular Issures, Techniques and Horizons TM, XV 5.1.	
		WILLIAM C. KRUPSKI, MD, Surgical Repair Is Better Than EVAR For Most AAAs: The Case For Has Strengthened In The Last Year, 28th Global: Vascular and Endovascular Issures, Techniques and Horizons TM, XV 1.1-1.3.	
		ROGER M. GREENHALGH, MD, Why Do We Still Need Randomised Controlled Trials For EndoVascular Aneurysm Repair (EVAR)?, Combined Session: Vascular Surgery and Interventional Radiology, V 1.1-1.2.	
		WILLIAM D. TURNIPSEED, MD, Minimal Incision Aortic Surgery: Is It Better Than EVAR for Easy AAAs; For Difficult AAAs?, 28th Global: Vascular and Endovascular Issures, Techniques and Horizons TM, XV 3.1-3.2.	
		IVANCEV ET AL., Ten Top Tips for EVAR in Patients With Difficult Anatomy, 28th Global: Vascular and Endovascular Issures, Techniques and Horizons TM, X 12.1-12.3.	
		GOODMAN ET AL., Composite Endoluminal Grafting For Aneurysms With Angled Necks, 28th Global: Vascular and Endovascular Issures, Techniques and Horizons TM, X 9.1.	
		PROFESSOR PRF BELL, Access Difficulties In Endovascular Aneurysm Repair, Combined Session: Vascular Surgery and Interventional Radiology, VII 6.1-6.5.	
		RICHTER ET AL., Long-term Consequences Of Type II Endoleaks After EVAR: When Must They Be Treated?, Combined Session: Interventional Radiology and Vascular Surgery, IV 9.1-9.2.	

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449/PTO				Complete if Known
, Substitu	10 10 10 11 14-3/1 TO			Application Number	10/053,053
INF	ORMATION	DIS	CLOSURE	Filing Date	January 16, 2002
STATEMENT BY APPLICANT				First Named Inventor	Lee L. Swanstrom
	/lea se many cha	ate se n	neacean)	Art Unit	3731
(Use as many sheets as necessary)				Examiner Name	Not yet assigned.
Sheet	4	of	11	Attorney Docket Number	3395-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		MARK F. FILLINGER, MD, Advances In Imaging For Vascular And Endovascular Surgery, 28th Global: Vascular and Endovascular Issues, Techniques and Horizons TM, XIII 2.1-2.11.	
		GLOVICZKI ET AL., High Morbidity And Mortality Of Contemporary Open Surgical Repairs Of Ruptured Abdominal Aortic Aneurysms, Combined Session: Vascular Surgery and Interventional Radiology, VI 1.1-1.3.	
		MONEY ET AL., Aortic Neck Angulation Predicts Adverse Outcome With Endovascular Abdominal Aortic Aneurysm Repair, Combined Session: Vascular Surgery and Interventional Radiology, IV 8.1-8.2.	
		WILSON ET AL., Clinical Experience With The LIFEPATH AAA Endovascular Graft For Repair Of Abdominal Aortic Aneurysms, 28th Global: Vascular and Endovascular Issues, Techniques and Horizons TM, XII 7.1-7.2.	
		WOLF STELTLER, MD, PHD, Continuous Improvements In EVAR Above Standard Surgical Repair For Most Patients, 28th Global: Vascular and Endovascular Issues, Techniques and Horizons TM, XV 2.1.	
		RAITHEL ET AL., Comparative Advantages And Disadvantages Of Various Available Endografts For AAA Repair, 28th Global: Vascular and Endovascular Issues, Techniques and Horizons TM, X 1.1-1.2.	
		PETER L. HARRIS, MD, What Can Multicentre Registries Tell Us About Endovascular Aneurysm Repair (EAR) That Single Centre Reports Do Not?, 28th Global: Vascular and Endovascular Issues, Techniques and Horizons TM, X 2.1.	
•• .		BUTH ET AL., Causes And Outcomes Of Open Conversion And Aneurysm Rupture After EVAR: Can Type II Endoleaks Be Dangerous?, 28th Global: Vascular and Endovascular Issues, Techniques and Horizons TM, X 5.1-5.5.	
		NUNN ET AL., Problems Resulting From Interaction Of Fabric And Stent Components Of Endografts: Can They Be Prevented?, Combined Session: Vascular Surgery and Interventional Radiology, V 6.1-6.3.	
		ROBERT B. RUTHERFORD, MD, Late Failure Modes With Endovascular Aortic Aneurysm Repair: Implications For The Future, 28th Global: Vascular and Endovascular Issues, Techniques and Horizons TM, X 3.1-3.5.	

Examiner	Date	·
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JAN 3 0 2006

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known		
Capacitate to room 1770.	Application Number	10/053,053		
INFORMATION DISCLOSURE	Filing Date	January 16, 2002		
STATEMENT BY APPLICANT	First Named Inventor	Lee L. Swanstrom		
(Use as many sheets as necessary)	Art Unit	3731		
(Use as many sneets as necessary)	Examiner Name	Not yet assigned.		
Sheet 5 of 11	Attorney Docket Number	3395-US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BARRY T. KATZEN, MD, Update Of The Excluder (W.L. GORE) Endoprosthesis, 28th Global: Vascular and Endovascular Issues, Techniques and Horizons TM, X 8.1-8.3.	
		AUTHOR UNKNOWN, Abdominal Aortic Aneurysm: Screening for a Silent Threat.	
		PARODI ET AL., Ten-Year Experience with Endovascular Therapy In Aortic Aneurysms, J Am Coll Surg, January 2002, Volume 194, No. 51, S58-S66.	
		SWANSTROM ET AL., Laparoscopic assisted endovascular stenting of abdominal aortic aneurysms, Marseille Symposium, pp.114-122.	
		MARIN ET AL., Varying Strategies For Endovascular Repair of Abdominal and Iliac Artery Aneurysms, Surgical Clinics of North America, August 1998, Volume 78, Number 4, pp. 631-645.	
		KOLVENBACH ET AL., Laparoscopy-assisted aneurysm resection as a minimal invasive alternative in patients unsuitable for endovascular surgery, Journal of Vascular Surgery, August 2001, Volume 34, Number 2, pp.216-221.	
		DION ET AL., Minimally invasive surgery and the vascular specialist, Surgical Endoscopy, August 1999, Volume 13, pp. 735-736, Springer-Verlag, New York.	
		KRAJCER ET AL., Unusual Case of AneuRx Stent-Graft Failure Two Years After AAA Exclusion, J Endovasc Ther, 2001, 8:465-471.	
		ARKO ET AL., Type-II Endoleaks Following Endovascular AAA Repair: Preoperative Predictors and Long-term Effects, J Endovasc Ther, 2001, 8:503-510.	
		FLORA ET AL., Micromovements at the Aortic Aneurysm Neck Measured During Open Surgery With Close-Range Photogrammetry: Implications for Aortic Endografts, J Endovasc Ther, 2001, 8: 511-520.	

	·	
Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

JAN 3 0 2006

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

7-	te for form 1449/PTO				Complete if Known		
		Application Number	10/053,053				
INFORMATION DISCLOSURE				Filing Date	January 16, 2002		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Lee L. Swanstrom		
	(Use as many she	ote ae n	ococcand	Art Unit	3731		
	(Use as many sne	eis as ii	ecessary)	Examiner Name	Not yet assigned.		
Sheet	6	of	11	Attorney Docket Number	3395-US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		STANLEY ET AL., Evaluation of Patient Selection Guidelines for Endoluminal AAA Repair With the Zenith Stent-Graft: The Australasian Experience, J Endovasc Ther, 2001, 8:457-464.	
		SCHLENSAK ET AL., Serious complications that require surgical interventions after endoluminal stent-graft placement for the treatment of infrarenal aortic aneurysms, Journal of Vascular Surgery, August 2001, Volume 34, Number 2, pp.198-203.	
		WESLEY S. MOORE, MD, Endovascular Repair of Abdominal Aortic Aneurysm, Guidant/Endovascular Technologies.	
		JONES ET AL., Endovascular Grafting for Repair of Abdominal Aortic Aneurysm, Critical Care Nurse, August 2000, Volume 20, Number 4, pp 38-51.	
		BERENS ET AL., Laparoscopic vascular surgery: Four case reports, Journal of Vascular Surgery, July 1995, Volume 22, Number 1, pp. 73-79.	
		EDOGA ET AL., Laparoscopic surgery for abdominal aortic aneurysms, Surgical Endoscopy, August 1998, Volume 12, pp. 1064-1072, Springer Verlag, New York.	
		AHN ET AL., Standards and Guidelines for Abdominal Aortic Aneurysm Repair, J Endovasc Surg, 1995, 2:376-377.	
		WALD ET AL., AAA Should Give Patients More Mileage, A.G. Edwards, September 4, 2001.	
		CANALES ET AL., The surgical suite meets the new health economy, Correspondence address, Accepted January 22, 2001.	
	•	AUTHOR UNKNOWN, Least-Invasive Cardiac and Vascular Surgery, Medpro Month, July/August 1996.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

**Application Number** 

Attorney Docket Number

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Filing Date January 16, 2002
First Named Inventor Lee L. Swanstrom

(Use as many sheets as necessary)

of

11

sector, BBI report, June 2000.

Sheet

Art Unit 3731

Examiner Name Not yet assigned.

3395-US

10/053,053

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Cite Examiner T<sup>2</sup> No.1 Initials\* the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. DAVID FIRN, Emerging Opportunities for Coronary Stents, Clinica Reports, Industry Alert, CBS 671, December 1996, PJB Publications Ltd., AUTHOR UNKNOWN, Endovascular AAA Repair, Medtech Insight, Business & Technology Briefs, November-December 2000, p. 221. AUTHOR UNKNOWN, AAA and Vascular Device Start-Ups, Start-Up, November 1998, Windhover Information Inc.. AUTHOR UNKNOWN, AAA Graft Market, Medtech Insight, Business & Technology Briefs, November-December 2000, pp. 287-288. AUTHOR UNKNOWN, Endovascular Stent-Grafts: Catching Up with Europe, Medpro Month, August 1999, pp. 205-207. DEBORAH ERICKSON, Market Pressure, Part II: Devices Cool Down, Start-Up, November 1998, Windhover Information Inc.. AUTHOR UNKNOWN, Stent-Grafts: The Tortuous Road Ahead, MDI paper, April 1998. LACY RAINEY, MS, The U.S. AAA Stent-Graft Market: What is the most important factor in developing this emerging market?, April 18, 2001.

Examiner	 Date	
Signature	 Considered	

MICHAEL SIMONSEN, New Segments emerging in interventional radiology

DAVID A. GRUBER, MD, Less-Invasive Vascular Intervention: From Head to

Toe, Vector Securities International, July 28, 1997, pp.1-20.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if Known		
Jubsulu	te for form 1443/1-10			Application Number	10/053,053	
INFORMATION DISCLOSURE			CLOSURE	Filing Date	January 16, 2002	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Lee L. Swanstrom	
	(Use as many sh	oote se n	acassand	Art Unit	3731	
	Ose as many sir	CC13 03 //	ecessary	Examiner Name	Not yet assigned.	
Sheet	8	of	11	Attorney Docket Number	3395-US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		AUTHOR UNKNOWN, Cook, Baxter Endovascular AAA Grafts Among Second Wave in PMA Process, The Gray Sheet, August 16, 1999.	
		AUTHOR UNKNOWN, Vaxcel Chronic Dialysis Catheter, New Procedural Kit Options with Choice of Metal or Plastic Tunneler, Boston Scientific Medi-Tech, 2001, Boston Scientific Corporation.	
		AUTHOR UNKNOWN, Exxcel TM Soft ePTFE Vascular Graft, Boston Scientific Medi-Tech, 2001, Boston Scientific Corporation.	
		AUTHOR UNKNOWN, Hemashield Vantage Vascular Graft, Boston Scientific Medi-Tech, 2000, Boston Scientific Corporation.	
		AUTHOR UNKNOWN, Talent TM Endoluminal Stent-Graft System, 1997, World Medical Manufacturing Corporation.	
		AUTHOR UNKNOWN, Vanguard TM Endovascular Aortic Graft, Meadox Medicals Inc., 1996, Boston Scientific Corporation.	
		AUTHOR UNKNOWN, Passager TM Stent Graft, Quality Meets Innovation in Peripheral Vascular Treatment, Meadox Medicals Inc., 1997, Boston Scientific Corporation.	
		AUTHOR UNKNOWN, Guidant Annoure for life, 1996, Endovascular Technologies, Inc	
		AUTHOR UNKNOWN, Ancure User Guide, Guidant Cardiac & Vascular Surgery Group, Notice of Approval 9-28-1999, pp.1-24.	
		AUTHOR UNKNOWN, Guidant Ancure Instructions For Use, Guidant Cardiac & Vascular Surgery Group, 8-4-1999, pp. 1-5.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office P.O. Roy 1450, Alexandria VA 2313-1459. DO NOT SEND THESE OR COMPLETED EXPLOSITION. Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE or the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	e for form 1449/PTO				Complete if Known		
Cubstitu	0 10/10/11/14-07/10			Application Number	10/053,053		
INFORMATION DISCLOSURE				Filing Date	January 16, 2002		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Lee L. Swanstrom		
(Use as many sheets as necessary)				Art Unit	3731		
	Ose as many sne		ecessary)	Examiner Name	Not yet assigned.		
Sheet	9	of	11	Attorney Docket Number	3395-US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		AUTHOR UNKNOWN, Ancure TM Endograft System, Essential Prescribing Information (EPI) and Operator's Instructions For Use, Guidant Cardiac & Vascular Group, 1999, pp. 1-32.	
		AUTHOR UNKNOWN, Medtronic AneuRX Endovascular AAA Graft Should Be Approved - FDA Panel, The Gray Sheet, June 28, 1999	
		MATSUMURA ET AL., AAA graft picture, Journal of Vascular Surgery, August 2001, Volume 34, Number 2, pp. 193-194.	
		DAVID W. FEIGAL, JR., MD, MPH, FDA Public Health Notification: Problems with Endovascular Grafts for Treatment of Abdominal Aortic Aneurysm (AAA), April 27, 2001.	
- " " "		AUTHOR UNKNOWN, Summary of Safety and Effectiveness Data, The AneuRx Stent Graft System, P 990020, 9-27-1999, pp. 1-47.	
		AUTHOR UNKNOWN, Only One, 1995, Johnson & Johnson Interventional Systems.	
		AUTHOR UNKNOWN, Endologix PowerLink TM System, Endologix, Inc	
		ISHIMARU ET. AL., Endovascular AAA Repair by PowerWeb Unibody Stent Graft, Presented at the 25th World Congress ISCVS, September 2001, Cancun, Mexico.	
		RODNEY A. WHITE, MD, Clinical and design update on the development and testing of a one-piece, bifurcated, polytetrafluoroethylene endovascular graft for abdominal aortic aneurysm exclusion: The Endologix device, Journal of Vascular Surgery, February 2001, Volume 33, Number 2, S154-S156.	
_		AUTHOR UNKNOWN, Moving from AAAs to carotid and peripheral vascular disease, Endotex Interventional Systems Inc., Start-Up, November 1998, Windhover Information Inc.	

Examiner	Date	-
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this build be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/053,053 INFORMATION DISCLOSURE **Filing Date** January 16, 2002 STATEMENT BY APPLICANT **First Named Inventor** Lee L. Swanstrom Art Unit 3731 (Use as many sheets as necessary) Examiner Name Not yet assigned. Attorney Docket Number Sheet 11 3395-US 10 of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		AUTHOR UNKNOWN, Goose Neck TM Snares and AAA Stent Graft Deployment, Microvena Corporation, White Bear Lake, MN.	
		AUTHOR UNKNOWN, Ultra-Select Guidewires New 45 degree angled tip, Microvena Corporation, White Bear Lake, MN.	
		AUTHOR UNKNOWN, Corvita Endoluminal Graft, Corvita Corporation, Miami, FL.	
		AUTHOR UNKNOWN, Schneider 1997 Product Guide, WallStent Endoprosthesis, Schneider (USA) Inc., 1997.	
		FRANK J. CRIADO, MD, On Becoming an Endovascular Surgeon, Editorial, J Endovasc Surg, 1996; 3:140-145.	
		VARIOUS AUTHORS, International Congress XV on Endovascular Interventions, Attack on America: Impact on Endovascular Interventions, Abstracts enclosed: Monday, February 11, 2002, Phoenix, AZ.	
		VARIOUS AUTHORS, International Congress XV on Endovascular Interventions, Session IV, Tools of the Trade: Are We Making Progress?, Abstracts enclosed: Tuesday, February 12, 2002, Phoenix, AZ.	
		VARIOUS AUTHORS, International Congress XV on Endovascular Interventions, Session VI, Do the Results Justify the Means?, Abstracts enclosed: Wednesday, February 13, 2002, Phoenix, AZ.	
		VARIOUS AUTHORS, International Congress XV on Endovascular Interventions, Session X, Peripheral Interventions: Is there a Light at the End of the Tunnel?, Abstracts enclosed: Thursday, February 14, 2002, Phoenix, AZ.	
		ROBERT LUDEMANN, MD, PHD, and LEE L. SWANSTROM, MD, Totally Laparoscopic Abdominal Aortic Aneurysm Repair, Seminars in Laparoscopic Surgery, Volume 6, Number 3, September 1999, pp. 153-163.	

Examiner	 Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JAN 30 1006 BY

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of a collection of information unless it contains a valid OMB control number.

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numbe

Substitute for form 1449/PTO	Complete if Known		
Substitute for form 1443/110	Application Number	10/053,053	
INFORMATION DISCLOSURE	Filing Date	January 16, 2002	
STATEMENT BY APPLICANT	First Named Inventor	Lee L. Swanstrom	
(Use as many sheets as necessary)	Art Unit	3731	
(USE as many sneets as necessary)	Examiner Name	Not yet assigned.	
Sheet 11 of 11	Attorney Docket Number	3395-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MORTON H. FRIEDMAN and ZHAOHUA DING, Viability of the planarity of the human aortic bifurcation, Medical Engineering & Physics, September 1998, Volume 20, Issue 6, pp.469-472.	
·			
		·	
	-		
		·	
	1		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: